The globalization of clinical research has seen international multicenter trials become standard, partially in response to the increasing demand to clinical trials that cover the three major markets: Europe, USA and China.
Studies of new drugs that include Chinese subjects present a particular challenge, due to strict regulations of the Chinese National Medical Products Administration (NMPA), as it is nearly impossible to export blood samples from China for analysis at labs in other countries. In order to provide better services for comprehensive, harmonized clinical trials that include Chinese subjects, MLM Medical Labs GmbH has entered a strategic alliance with the renowned Teddy Clinical Research Laboratory in Shanghai.
Teddy Lab is a joint venture between Hangzhou Tigermed Co. Ltd and Zhejiang DIAN Diagnostics Co., Ltd.. Like MLM, Teddy is exclusively dedicated to provide central lab services for clinical trials. MLM chose Teddy Lab as a partner after careful scrutiny in a multi-level selection process, observing considerable parallels between the two laboratories: “When we visited Teddy Lab in Shanghai, we were impressed with their instrument portfolio and experienced, well-trained staff. We also saw a perfect match in the company philosophy and strategy as a central lab for clinical trials,” stated Prof. Stephan Wnendt, CEO of MLM Medical Labs.
“A major common ground between our two labs is CAP-accreditation and considerable experience in multicenter clinical trials“, added Wnendt. Both central labs cover the full value chain from study-specific kit design, through extensive analytical services and data management to detailed reporting.
Dr. Shirley Xu, CEO of Teddy Clinical Research Laboratory, commented: “We look forward to this collaboration with MLM Medical Labs. After joining the ICH in 2017, China is increasingly open to the world clinical research market and contact to European customers. We see our lab as one of the leaders of this openness.”
Prof. Wnendt shares Dr. Xu’s great optimism. “We forged a successful strategic alliance with Cenetron Diagnostics in Austin, Texas in 2015. We’re delighted to expand our business to the Chinese market so that we can provide our clients even better support in conducting their transcontinental clinical trials.”